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Abstract Echistatin is a member of the disintegrin family of
peptides and a potent inhibitor of platelet aggregation and cell
adhesion. Echistatin binds to integrin KvL3 and KIIbL3 receptors
with high affinity. Binding is mediated by an RGD-containing
loop maintained in an appropriate conformation by disulfide
bridges. In this study, we have compared the binding character-
istics of echistatin iodinated by either lactoperoxidase or
chloramine T method. We show that echistatin labeled by
lactoperoxidase method binds to integrin KvL3 receptor with high
affinity and in a non-dissociable manner very similar to native
echistatin. In contrast, chloramine T-labeled echistatin can
rapidly dissociate from the receptor. We demonstrate that
chloramine T reaction results in the addition of an extra oxygen
to the methionine residue adjacent to the RGD motif in
echistatin. Modeling studies and molecular dynamic simulation
studies show that the extra oxygen atom on the methionine
residue can form hydrogen bonds with the glycine and aspartic
acid residues of the RGD motif. These structural changes in
echistatin help explain the changes in the binding characteristics
of the molecule following chloramine T reaction.
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1. Introduction
Echistatin is a 49 amino acid peptide derived from the ven-
om of Echis carinatus and belongs to the disintegrin family of
peptides [1,2]. So far about 30 disintegrins have been isolated
and characterized from the venoms of many species of snakes
[1^3]. These disintegrins contain 49^84 amino acids and 8^14
cysteine residues linked by intramolecular disul¢de bonds
[4^6]. The three-dimensional structure of echistatin has been
determined in aqueous solution by nuclear magnetic reso-
nance (NMR) spectroscopy [7]. The sequence of echistatin
contains eight cysteine residues forming four disul¢de bridges
[1,8]. NMR-derived structure for echistatin reveals that the
RGD sequence is present in a loop between two L strands
of the protein protruding 14^17 Aî from the protein core.
The activity of echistatin depends on the appropriate pairing
of eight cysteines by S-S bridges, which maintain RGD-con-
taining loop in an appropriate conformation. Echistatin binds
with high a⁄nity to several integrins and is a potent inhibitor
of platelet aggregation and cell adhesion.
Integrins are a family of structurally related heterodimeric
cell surface receptors that mediate cell-cell and cell-matrix
interactions [9^11]. Integrins bind to proteins present in the
extracellular matrix and mediate anchorage and convey sig-
nals that regulate cell growth, di¡erentiation and migration
[11^13]. Many of the integrin receptors bind to a common
recognition sequence, comprising arginine-glycine-aspartic
acid (RGD) in the macromolecular ligands such as ¢bronec-
tin, vitronectin, von Willebrand factor and ¢brinogen [13].
The integrin KvL3 is expressed on endothelial cells, smooth
muscle cells, osteoclasts, melanoma and other cell types where
it plays an important role in physiological processes that in-
clude angiogenesis and tissue repair, as well as pathological
conditions such as osteoporosis, tumor cell metastasis and
tumor-induced angiogenesis [14]. Recent results indicate a
key role for this integrin in a signaling event critical for the
survival and ultimate di¡erentiation of vascular cells under-
going angiogenesis in vivo [14^16]. Echistatin is a more potent
inhibitor of ligand binding to puri¢ed KvL3 and K5L1 than to
puri¢ed KIIbL3.
In this study, we show that echistatin radiolabeled with 125I
by chloramine T method shows strikingly di¡erent binding
characteristics to integrin KvL3 receptor compared to either
native or lactoperoxidase-labeled 125I-echistatin. Mass spec-
trometric analysis of the chloramine T-treated echistatin indi-
cates the addition of an extra oxygen atom to the methionine
residue adjacent to the RGD sequence. Modeling studies and
molecular dynamic simulation studies show that the extra
oxygen atom on the methionine residue can form hydrogen
bonds with the glycine and aspartic acid residues of the RGD
motif. These structural changes in echistatin account for the
changes in the binding characteristics of the molecule.
2. Materials and methods
2.1. Materials
Synthetic RGD-containing peptides were purchased from Gibco-
BRL (Gaithersburg, MD, USA). Octyl-L-D-glucopyranoside and
Nonidet-P-40 were purchased from Sigma Chemical Company (St.
Louis, MI, USA). Microlite-2 plates were obtained from Dynatech
Corporation (Chantilly, VA, USA). KvL3-speci¢c (LM609) monoclo-
nal antibodies and LM609 coupled to a⁄gel matrix were purchased
from Chemicon International Inc., (Temecula, CA, USA). 125I-echis-
tatin labeled by chloramine T method or by lactoperoxidase method
to a speci¢c activity of 2000 Ci/mmole were from Amersham Interna-
tional (Chicago, IL, USA). Echistatin was purchased from Bachem
(Torrence, CA, USA).
2.2. Protein puri¢cation and solid phase receptor binding assay
KvL3 was puri¢ed as described by Orlando and Cheresh [18]. The
receptor binding assay was performed as described previously [17,18].
2.3. Peptide synthesis
The peptide fragments derived from echistatin (residue 20 to 32)
were synthesized on an ABI 431A peptide synthesizer using Fmoc
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chemistry and an Fmoc Amide resin (Applied Biosystems, Foster
City, CA, USA). The side chains of trifunctional residues were pro-
tected by tert-butyl (for Asp and Tyr), trityl (for Cys), tert-butyl-
oxycarbonyl (for Lys), and 2,2,4,6,7-pentamethyldihydrobenzofuran-
5-sulfonyl (for Arg). The peptides were cleaved and deprotected by
concentrated tri£uoroacetic acid (80% TFA) in the presence of scav-
engers (4% each of phenol, H2O, thioanisole, ethanedithiol, and tri-
isopropylsilane). The cleaved peptides were extracted into cold ethyl
ether. The crude peptides were puri¢ed by reversed phase high per-
formance liquid chromatography. The molecular masses of the puri-
¢ed peptides were con¢rmed by mass spectroscopy. Chloramine T and
lactoperoxidase treatments of echistatin and peptides were carried out
in the absence of NaI125 as suggested by the manufacturer (Amersham
International, Chicago, IL, USA).
2.4. Mass spectrometry
Electrospray mass spectra were acquired on a Perkin-Elmer Sciex
(Concord, Canada) API III triple-quadrupole mass spectrometer
equipped with an atmospheric pressure ion source, kept at 60‡C,
and an ion-spray interface [19,20]. Echistatin and the CT-/LP-treated
products were dissolved in 0.1% aqueous TFA to a concentration in
the low mM range (ca.5 pmol/ml). The samples were then infused into
the ion-spray source of the mass spectrometer at a £ow rate of 5 ml/
min for the duration of several full-scan spectra. The ¢nal spectrum
was an averaged sum of several scans [21,22] from m/z 600 to 2000
(MCA mode) at a scan rate of 3 s/scan. The average molecular weight
was derived from all the observed charge states with an accuracy of
1^2 Da from the expected mass.
Plasma desorption mass spectrometric analysis of the 13 amino acid
synthetic echistatin peptides and their CT-/LP-treated products was
performed using a BIOION 20 californium-252 time-of-£ight mass
spectrometer set at an acceleration voltage of 15 kV. The samples
were dissolved in 2:1 (v/v) aqueous TFA/ethanol and spin-dried prior
to their introduction into the source of the mass spectrometer [22].
2.5. Development of three-dimensional structure of chloramine
T-labeled echistatin using homology methods
The three-dimensional structure of modi¢ed echistatin was built
using the coordinates of echistatin determined experimentally using
NMR methods [4]. The change in methionine residue was incorpo-
rated on ESV graphics system using FRODO package [23] and re¢ned
for stereochemistry optimization. The model was then energy-mini-
mized using conjugate gradient minimizing method of Powell [24].
The energy-minimized structure of modi¢ed echistatin was further
re¢ned using molecular dynamics simulation methods using X-
PLOR [25]. Comparison of 3D structures of echistatin and echistatin
with methionine sulfoxide at position 28 showed that both the struc-
tures were very similar except for small local changes around methio-
nine residue (Fig. 6). Various molecular dynamics protocols used for
developing the structure of echistatin with methionine sulfoxide, and
the searches for conformational space for global minima, converged
to the same three-dimensional structure. The total energy of echistatin
with methionine sulfoxide compared well with that of the native echi-
statin.
3. Results and discussion
3.1. Binding characteristics of lactoperoxidase and chloramine
T-labeled 125I-echistatin to puri¢ed KvL3 receptor
Echistatin was radiolabeled with 125I either by lactoperoxi-
dase (LP) or chloramine T (CT) method and its binding to
puri¢ed KvL3 was measured using a solid phase receptor bind-
ing assay as described in Section 2 [17,26]. Incubation of pu-
ri¢ed KvL3 (10 ng) with increasing concentrations of LP- or
CT-labeled echistatin for 3 h resulted in a saturable and spe-
ci¢c binding (Fig. 1). Non-speci¢c binding was evaluated by
carrying out the binding assay in the presence of 200-fold
molar excess of echistatin and was typically less than 10 per-
cent of the total binding. The data were analyzed by non-
linear regression using graph-pad prism [17]. LP-labeled echi-
statin binds to KvL3 with an apparent Kd of 0.3 nM, whereas
CT-labeled echistatin exhibited a Kd value of 1 nM (Fig. 1A
and B). The Bmax value for the binding reactions using the two
ligands was 750 pmoles/mg protein. Scatchard analysis of the
binding data using ligand computer program gave identical
results. Thus CT-labeled echistatin has a slightly lower a⁄nity
for KvL3 receptor compared to LP-labeled echistatin.
Next, we compared the Ki values for the various RGD
peptides in competition type experiments using either LP- or
CT-labeled echistatin. The concentrations required for half-
maximal inhibition of the binding of LP-labeled echistatin
to KvL3 receptor were calculated to be 0.3 þ 0.06 nM for echi-
statin and 445 þ 102 nM and 183 þ 22 nM for linear RGD
peptide and cyclic RGD peptide respectively (Fig. 2A). The
corresponding values for CT-labeled echistatin were,
0.3 þ 0.06 nM for echistatin and 6 þ 0.7 nM and 1 þ 0.20 nM
for linear and cyclic RGD peptide respectively (Fig. 2B). A
linear hexamer peptide containing RGE sequence failed to
compete for the binding of either LP- and CT-labeled echi-
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Fig. 1. Scatchard analysis of LP- or CT-labeled 125I-echistatin bind-
ing to puri¢ed KvL3 integrin receptor. Saturation binding isotherms
of LP- (A) or CT- (B) labeled 125I-echistatin binding to KvL3 recep-
tor were determined in a solid phase receptor binding assay as de-
scribed in Section 2. Integrin KvL3 puri¢ed from human placenta
was coated at a concentration of 10 ng/well onto Microlite-2 plates
and incubated with various concentrations (0.05^5 nM) of 125I-echi-
statin for 3 h at room temperature. Bound ligand concentration was
determined by solubilizing the counts with boiling 2 N NaOH and
subjected to gamma counting. Non-speci¢c binding was evaluated
by carrying out the binding assay in the presence of 200-fold molar
excess of cold echistatin and was subtracted from the total binding
to calculate speci¢c binding. Each data point is an average of tripli-
cate measurements in which the error was less than 5% of the total
binding. To derive the a⁄nity of the interaction between echistatin
and KvL3, the data shown in panel A were analyzed by non-linear
regression analysis using graph-pad prism program.
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statin to KvL3 receptor (data not shown). Even though LP-
and CT-labeled 125I-echistatin bind to integrin KvL3 receptor
with similar a⁄nities, the concentrations of linear and cyclic
RGD peptides required for half-maximal inhibition were
strikingly di¡erent. Signi¢cantly higher concentrations of
RGD peptides were required for competing the binding of
LP-labeled echistatin to KvL3 compared to CT-labeled echi-
statin. The Ki values for unlabeled echistatin in these compe-
tition experiments are identical for echistatin labeled by the
two methods.
Next, we determined the e¡ect of varying the incubation
times of the binding reactions on the Ki values for linear
and cRGD peptides using the two ligands. In these experi-
ments, LP- or CT-labeled echistatin was incubated for di¡er-
ent intervals of time with KvL3 receptor in the presence of
increasing concentrations of cRGD peptide and the amount
of ligand bound to the receptor was determined in the solid
phase receptor binding assay. As shown in Fig. 2C and D, the
Ki values of cRGD peptide increased signi¢cantly with longer
incubation times (2 h vs. 16 h), with LP-labeled echistatin.
The concentrations of cRGD required to compete for half-
maximal binding of LP-labeled echistatin to KvL3 during a 2 h
incubation period was 292 þ 68 nM and the corresponding
value for 16 h incubation was 2760 þ 250 nM. However, the
corresponding Ki values for the cRGD peptide using CT-la-
beled echistatin were 4 þ 1 nM (2 h) and 2.3 þ 0.45 nM (16 h)
(Fig. 2D). Hence, higher concentrations of cRGD peptide
were required to compete for the binding of LP-labeled echi-
statin to KvL3 receptor compared to CT-labeled molecule and
this value increased proportionally with longer incubation
times for LP-labeled echistatin. In contrast, the concentrations
of cRGD peptide required to compete for half-maximal bind-
ing of CT-labeled echistatin did not change dramatically with
an increase in incubation time.
3.2. Chloramine T-labeled 125I-echistatin binds to KvL3
receptor in a dissociable manner
To understand the biochemical basis for the di¡erences in
the binding characteristics of LP- and CT-labeled echistatin,
we determined the o¡-rate kinetics of the two ligands bound
to KvL3 receptor. In this experiment, LP- or CT-labeled 125I-
echistatin was incubated with KvL3 receptor for 3 h, the un-
bound ligand was removed and the wells were washed with
binding bu¡er followed by the addition of either binding
bu¡er or increasing concentrations of unlabeled competitors.
Under these conditions, LP-labeled 125I-echistatin bound to
the KvL3 receptor showed very little dissociation in the pres-
ence of either cold echistatin or linear and cRGD peptides
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Fig. 2. Competition of RGD peptides for the binding of either LP- or CT-labeled echistatin to KvL3 receptor. A: Puri¢ed receptor was coated
onto Microlite-2 plates at a concentration of 50 ng/well as described above. LP- (A) or CT- (B) labeled 125I-echistatin was added to the wells
to a ¢nal concentration of 0.05 nM in binding bu¡er (50 Wl/well) in the presence of di¡erent concentrations of the competing ligands. Cold un-
labeled echistatin, GRGDSP, and Gpen RGDSp peptides dissolved in binding bu¡er at the concentrations indicated were added to the wells
before the addition of radioligand. After a 3 h incubation at room temperature, the wells were washed thoroughly with binding bu¡er and ra-
dioactivity was determined using Top count (Packard). E¡ect of varying the incubation times of the receptor binding reactions on the concen-
trations of the various competitors required for half-maximal binding (C and D). LP- (C) or CT-labeled (D) 125I-echistatin was incubated with
KvL3 receptor in the presence of various concentrations of peptides for 2 or 16 h, the wells were washed with binding bu¡er and radioactivity
was determined using Top count (Packard). All measurements were done in triplicate with standard deviations less than 10%.
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(Fig. 3A), indicating that LP-labeled echistatin binds to
KvL3 in a non-dissociable manner. When the receptor was
saturated with native unlabeled echistatin for 3 h before re-
moving the unbound ligand and replaced with radiolabeled
ligand, there was very little binding, suggesting that native
echistatin also binds to KvL3 receptor in a non-dissociable
manner. In contrast, when CT-labeled echistatin was used in
these experiments, unlabeled echistatin, linear and cRGD pep-
tides were able to displace the bound ligand indicating that
CT-labeled echistatin binds to KvL3 receptor in a dissociable
manner (Fig. 3B). Thus chloramine T reaction seemed to alter
the protein in such a way that its interaction with the receptor
was signi¢cantly altered compared to either native echistatin
or LP-labeled echistatin. Lactoperoxidase labeling reaction
seemed to preserve the binding characteristics of the native
molecule.
To quantitate the dissociability of the CT-labeled echistatin,
its rate of dissociation was determined under dilution condi-
tions rather than competitive displacement. After saturation
of the receptor with CT-labeled 125I-echistatin, the radioligand
was removed and replaced with bu¡er. At speci¢c time points,
the presence of ligand was quantitated both in the aqueous
phase and that which was receptor associated. The dissocia-
tion rate constant was calculated from simple ¢rst-order ki-
netics as described by the following equation: ln(LR)/
LR =3k31t. As shown in Fig. 3C, the CT-labeled echistatin
rapidly dissociates from the receptor into the aqueous phase
with a dissociation rate of 3.7U1034 s31. Previous studies
have shown that vitronectin binds to integrin KvL3 in a non-
dissociable manner, whereas the binding of an RGD peptide
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Fig. 3. Chloramine T-labeled 125I-echistatin binds to KvL3 receptor
in a dissociable manner. A: The dissociability of the lactoperoxi-
dase-labeled 125I-echistatin was determined by preincubating the re-
ceptor with radiolabeled echistatin for 3 h and removing the un-
bound ligand, washing with binding bu¡er and then incubating with
either bu¡er or 50 nM of cold echistatin or 500 nM of linear RGD,
or 500 nM of cyclic RGD peptide for di¡erent times. The concen-
tration of bound ligand was determined at various times as de-
scribed in the legend to Fig. 1. The amount of labeled ligand bound
to KvL3 was given an arbitrary value of 100 percent. All points rep-
resent triplicate determinations with error of less than 5%. B: The
experiment was repeated as described above using CT-labeled echi-
statin. C: Measurement of the dissociation kinetics of CT-labeled
125I-echistatin from KvL3. To determine the dissociation rate con-
stant, CT-labeled 125I-echistatin at 1 nM concentration was incu-
bated with KvL3 receptor coated onto 96-well Microlite-2 plates for
3 h at room temperature. The wells were washed thoroughly fol-
lowed by the incubation of 100 Wl/well of blocking/binding bu¡er.
At the times indicated, the bu¡er was withdrawn and the wells were
washed twice with binding bu¡er and the bound radioactivity was
determined as described in the legend to Fig. 1. Non-speci¢c bind-
ing was measured by the coincubation of excess echistatin peptide
and represented 10 percent of the total binding. All points were the
average of triplicates with error measurements of less than 5%.
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Fig. 4. Electrospray mass spectrometric analysis of the lactoperoxi-
dase and chloramine T-treated unlabeled echistatin. The electrospray
(ES) mass spectrum of echistatin was obtained by dissolving the
sample in 0.1% aqueous TFA (V5 pmol/Wl) and then infusing into
the ion-spray source at a £ow rate of 5 Wl/min. The deconvoluted
spectrum shown in panel A is derived from the observed charged
states with the most prominent being the +4, +5 and +6 states.
Similarly, the lactoperoxidase and chloramine T-treated unlabeled
echistatin was chromatographed and the major chromatographic
peak was isolated and subjected to ES mass spectrometric analysis.
The respective deconvoluted ES mass spectra shown in panels B
and C indicate that the chloramine T treatment increased the molec-
ular weight of the peptide by 16 Da.
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derived from vitronectin is speci¢c but is completely dissoci-
able [18]. The interaction of KvL3 with vitronectin involves the
initial integrin-ligand recognition event, which is RGD de-
pendent and fully dissociable, followed by stabilization of
the receptor-ligand complex leading to a non-dissociable in-
teraction between these proteins. The dissociation rate con-
stant for 125I-vitronectin-derived peptide is 1.6U1034 s31
and is close to the value obtained for CT-treated echistatin.
These studies indicate that native and LP-labeled echistatin
bind to KvL3 in a non-dissociable manner similar to vitronec-
tin. In contrast, CT-labeled echistatin behaves very similar to
the RGD peptide derived from vitronectin.
3.3. Chloramine T reaction leads to the oxidation of methionine
residue in echistatin
To determine if there were any major structural changes in
echistatin induced by LP or CT treatment, unlabeled echista-
tin was subjected to LP or CT treatment in the absence of
NaI125 and the products were analyzed by ion-spray mass
spectrometry following puri¢cation of the products by
HPLC [19,20]. As shown in Fig. 4A, the measured molecular
mass of echistatin was 5416.5 consistent with the calculated
molecular mass of 5417 assuming four disul¢de bonds in the
protein. Lactoperoxidase treatment of echistatin did not
change the molecular mass of the protein (Fig. 4B). On the
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Fig. 5. Plasma desorption mass spectrometric analysis of the lactoperoxidase and chloramine T-treated echistatin (Met) and (N-Leu) peptides.
The plasma desorption (PD) mass spectrum of the echistatin (Met) synthetic peptide was obtained by dissolving the sample in 2:1 (v/v) 0.1%
aqueous TFA:ethanol, spin-drying and then analyzing them by PD mass spectrometry. The PD mass spectrum shown in panel A shows the
protonated molecular ion (MH). Similarly, the lactoperoxidase and chloramine T-treated echistatin (Met) peptides were chromatographed and
the major chromatographic peaks were isolated and subjected to PD mass spectrometric analysis. From the respective PD mass spectra shown
in panels B and C, the chloramine T treatment induces a 16 Da increase in the molecular weight. D and E: PD mass spectrometric analysis of
the lactoperoxidase and chloramine T-treated echistatin (N-leu) peptide. Echistatin (N-Leu) synthetic peptide was dissolved in 2:1 (v/v) 0.1%
aqueous TFA:ethanol by spin-drying and then analyzed by PD mass spectrometry. The PD mass spectrum of the major chromatographic peak
of the chloramine T-treated echistatin (N-Leu) peptide (panel E) was identical to that of the untreated echistatin (N-Leu) peptide (panel D).
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other hand, treatment of echistatin with chloramine T in-
creased the mass by 16 units, suggesting the addition of an
extra oxygen atom to the molecule (Fig. 4C).
To identify the precise amino acid residue in echistatin that
has picked up the oxygen atom, the CT-treated echistatin was
subjected to tryptic digestion followed by puri¢cation of the
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Fig. 6. Molecular structure for modi¢ed echistatin constructed using molecular dynamics simulation methods. Residue backbone and atoms are
color-coded as follows: green, hydrophobic; red, positively charged; blue, negatively charged; yellow, sulphur-containing residues; pink/pale
blue, hydrophilic; magenta, aspargine/glutamine; cyan, glycine/proline. the side chain atoms of amino acids RGDDM are shown in ball and
stick models. A: Ribbon drawing for the structure of modi¢ed echistatin developed using molecular dynamics simulation methods is shown.
The hydrogen bond distances between (Met-28) O- - -H-N (Gly-25) 2.72 Aî and (Met-28) O- - -H-N (Asp-26) 2.73 Aî are indicated in the ¢gure.
Residue backbone and atoms are color-coded as follows: green, hydrophobic; red, positively charged; blue, negatively charged; yellow, sul-
phur-containing residues; pink/pale blue, hydrophilic; magenta, aspargine/glutamine; cyan, glycine/proline. The side chain atoms of amino acids
RGDDM are shown in ball and stick models. B: Ribbon representation for the structure of native echistatin with the same color-coding
scheme of residues and atoms as described above.
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resulting peptides on HPLC and subjecting them to mass
spectrometric analysis. Tryptic digestion of echistatin gave a
complex pattern of peptides owing to the four disul¢de bonds
in the molecule. Hence, we used an alternate approach. It is
believed that the methionine residues are susceptible to oxida-
tion during chloramine T treatment [26]. Echistatin contains a
single methionine residue close to the RGD sequence [1^3].
Hence, a 13 amino acid long synthetic peptide corresponding
to the £exible RGD loop of echistatin was subjected to CT or
LP treatment and analyzed by mass spectrometric analysis. As
a control, we synthesized a 13 amino acid long peptide con-
taining a single substitution of norleucine residue for methio-
nine at position 9 in the peptide. The two peptides (Echi-Met
and Echi-N Leu) were treated with LP or CT and the prod-
ucts were puri¢ed by HPLC before subjecting them to plasma
desorption mass spectrometric analysis. As shown in Fig. 5A,
the measured molecular mass of the 13 amino acid long pep-
tide containing methionine was 1548. LP treatment of the
peptide did not alter the molecular weight of the peptide
(Fig. 5B). However, CT treatment of the peptide increased
the mass by 16 units suggesting that this peptide containing
the methionine residue has picked up an extra oxygen atom
(Fig. 5C). In contrast, the peptide containing norleucine sub-
stituted for methionine did not show any change in the mo-
lecular mass following CT treatment (Fig. 5D and E). LP-
treated peptide also gave identical spectra (results not shown)
These results indicate that the methionine residue following
the RGDD sequence is the one that picked up the oxygen
atom following treatment with chloramine T.
3.4. Development of three-dimensional structure of chloramine
T-labeled echistatin using homology methods
To gain insights into the structural changes induced by
chloramine T treatment of echistatin and to understand the
basis for the observed changes in the binding characteristics of
the molecule, we have developed the molecular structure for
echistatin with methionine sulfoxide as its residue 28 in the
native molecule. The structure of echistatin is predominantly a
loop structure with four non-standard turns. The folding
forces are largely due to the four disul¢de bridges between
all eight cysteine residues which are highly conserved in all
disintegrins. The eight cysteine residues in the protein, which
are widely distributed in the sequence, are localized in one
half of the molecule and the loop containing the RGD se-
quence and the C-terminal end is located in the other half
of the molecule (shown in Fig. 6). The RGD residues form
a loop at the tip of the hairpin formed by the two short
irregular antiparallel strands. The C-terminal end of the pro-
tein is in the proximity of the RGD loop and appears to be
most mobile. The three-dimensional structure developed for
the modi¢ed echistatin using molecular dynamics simulation
compared well with that of native echistatin. The model was
then re¢ned using conjugate gradient energy minimization
method by Powell [19]. The energy-minimized model was fur-
ther re¢ned using a slow-cooling simulated annealing molec-
ular dynamics procedure using X-PLOR [25]. The root-mean-
square (rms) deviations in CK coordinates between these two
protein structures is 0.7 Aî . The total energy calculated by
considering the various interactions, such as hydrogen bond-
ing, partial charge interactions, electrostatic, van der Waal’s
interactions, etc. for echistatin is 31112 kcal, and for modi¢ed
echistatin is 31155 kcal. The rms deviations in CK atoms
between echistatin and echistatin with methionine sulfoxide
at residues 28 is 0.7 Aî . In the native structure of echistatin
the methionine residue is tucked between the RGD loop and
the C-terminal loop which are antiparallel to each other
(shown in Fig. 6A). Although the environment of the methio-
nine sulfoxide residue in the structure of modi¢ed echistatin is
very similar to that of native molecule, the presence of oxygen
atom on methionine side chain forms two strong hydrogen
bonds with the main chain nitrogen atoms of residues Gly
and Asp of RGD loop. The two hydrogen bonds are (Met-
28) O- - -H-N (Gly-26) 2.65 Aî and (Met-28) O- - -H-N (Asp-
27) 2.67 Aî . The formation of such strong hydrogen bonds
between the side chain of methionine residue and the residues
in the RGD loop constrains the conformational £exibility of
the RGD loop and may contribute to the lower binding af-
¢nity of the molecule and to the dissociable nature of the
interaction with KvL3 receptor.
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